The New York-headquartered pharmaceutical and biotech company has faced growing criticism in recent months amid public concerns over the effectiveness of its Covid-19 vaccines and that of Paxlovid, a pill prescribed to treat coronavirus which has caused dozens of high-profile reinfections, also known as ‘breakthrough’ cases.